作者: Patricia L. Hibberd , Robert H. Rubin
DOI: 10.1016/S0891-5520(20)30327-5
关键词:
摘要: An ever-increasing population of immunocompromised individuals, including not only the burgeoning AIDS but also those patients whose host defenses have been damaged by a wide variety diseases and their therapies, requires prophylaxis against infectious diseases. Existing vaccines can provide some benefit, clinician must always be alert to fact that vaccine response cannot assumed such adjunctive measures as antimicrobial (i.e., amantadine during community-wide influenza outbreaks or penicillin pneumococcal infection in certain asplenics) and/or intravenous immunoglobulin administration should considered patients. In future, addition developing new vaccines, major effort devoted development immunoadjuvants would increase effectiveness administration.